Research Group Jonas Hedlund
Jonas Hedlund PhD, Associate professor, Team leader
Lower respiratory tract diseases- microbiological diagnostics and use of biomarkers for severity assessment and optimization of antibiotic therapy and prognosis.
In order to curb the global rise of antibiotic resistance, the WHO and the European Commission have set up action plans that primarily focus on improving the use of antibiotics. A key part of these plans is to actively develop rapid microbiological methods, enabling targeted antibiotic therapy. Streptococcus pneumoniae is the most common microbiological cause of pneumonia. Our group has shown that pneumococcal pneumonia can be quickly diagnosed with urinary antigen test and PCR on airway secretions, blood and pleural fluid. The research group's main research area covers microbiological diagnosis in pneumonia, severity assessment and optimization of antibiotic therapy.
Major research focus –study aims
- To gain access to clinically useful rapid microbiological methods for the detection of infectious agents, severity assessment tools and infection-specific monitoring for pneumonia.
- To study the extent to which the national treatment recommendations in community-acquired pneumonia are followed and how this is correlated to the prognosis.
- To study biomarkers, biomolecules and the etiologic spectrum in patients with pleural infections.
- To study denditritic cells (DC) in nasopharynx aspirates and blood from patients with respiratory viral infection in collaboration with Anna Smed Sörensen.
- To study whether it is possible to develop a prehospital decision support system for the emergency medical services for patients with severe infections – mainly respiratory tract infections - to an optimal level of healthcare.
Carl Spindler, PhD, Post Doctoral Fellow
Niclas Johansson, PhD, Post Doctoral Fellow
Quantitative detection of Streptococcus pneumoniae from sputum samples with real-time quantitative polymerase chain reaction for etiologic diagnosis of community-acquired pneumonia.
Diagn. Microbiol. Infect. Dis. 2008 Mar;60(3):255-61
Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden.
Vaccine 2008 Oct;26(43):5541-6
Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods.
Clin. Infect. Dis. 2010 Jan;50(2):202-9
Improvement of CRB-65 as a prognostic scoring system in adult patients with bacteraemic pneumococcal pneumonia.
Scand. J. Infect. Dis. 2011 Jul;43(6-7):448-55
Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia.
Scand. J. Infect. Dis. 2011 Aug;43(8):609-15
Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults--Swedish Society of Infectious Diseases 2012.
Scand. J. Infect. Dis. 2012 Dec;44(12):885-902
Improvement of CRB-65 as a prognostic tool in adult patients with community-acquired pneumonia.
BMJ Open Respir Res 2014 ;1(1):e000038
Procalcitonin levels in community-acquired pneumonia - correlation with aetiology and severity.
Scand. J. Infect. Dis. 2014 Nov;46(11):787-91
The IRIDICA PCR/Electrospray Ionization-Mass Spectrometry Assay on Bronchoalveolar Lavage for Bacterial Etiology in Mechanically Ventilated Patients with Suspected Pneumonia.
PLoS ONE 2016 ;11(7):e0159694
Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study.
Clin. Microbiol. Infect. 2017 Apr;23(4):247-252